Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
UBS
McKinsey
Fish and Richardson
Queensland Health
Citi
McKesson
Daiichi Sankyo

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,144,568

« Back to Dashboard

Which drugs does patent 9,144,568 protect, and when does it expire?

Patent 9,144,568 protects BENDEKA and is included in one NDA.

This patent has twelve patent family members in five countries.
Summary for Patent: 9,144,568
Title:Formulations of bendamustine
Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
Inventor(s): Sundaram; Srikanth (Somerset, NJ)
Assignee: EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ)
Application Number:14/714,578
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 9,144,568

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eagle Pharms BENDEKA bendamustine hydrochloride SOLUTION;IV (INFUSION) 208194-001 Dec 7, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,144,568

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,579,384 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration ➤ Subscribe
9,000,021 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration ➤ Subscribe
9,597,399 Formulations of bendamustine ➤ Subscribe
9,034,908 Formulations of bendamustine ➤ Subscribe
9,597,397 Formulations of bendamustine ➤ Subscribe
9,572,888 Formulations of bendamustine ➤ Subscribe
9,572,887 Formulations of bendamustine ➤ Subscribe
9,597,398 Formulations of bendamustine ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,144,568

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 6224064 ➤ Subscribe
European Patent Office 2827863 ➤ Subscribe
Japan 2015510939 ➤ Subscribe
European Patent Office 2827862 ➤ Subscribe
Japan 2015510940 ➤ Subscribe
China 104302291 ➤ Subscribe
China 107157988 ➤ Subscribe
Canada 2867343 ➤ Subscribe
China 104271135 ➤ Subscribe
Canada 2867295 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Covington
Medtronic
Healthtrust
Teva
Julphar
Daiichi Sankyo
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot